Body Mass Index and Major Adverse Cardiovascular Events: A Secondary Analysis Based on a Retrospective Cohort Study

Xiaobo Liu1, Peng Liu2

  • 1The Affiliated Hospital of Weifang Medical College, Shandong, China (mainland).

Insights

Overweight patients with stable coronary artery disease (CAD) have a lower risk of major adverse cardiovascular events (MACE) after percutaneous coronary intervention (PCI). The optimal body mass index (BMI) threshold for predicting MACE is 24.23 kg/m².

Area of Science:

  • Cardiology
  • Metabolic Health
  • Clinical Research

Background:

  • The relationship between Body Mass Index (BMI) and Major Adverse Cardiovascular Events (MACE) in patients with stable Coronary Artery Disease (CAD) remains controversial.
  • Existing research lacks clarity on whether different BMI categories influence cardiovascular outcomes post-intervention.

Purpose of the Study:

  • To investigate the association between BMI and MACE in patients with stable CAD undergoing elective Percutaneous Coronary Intervention (PCI).
  • To determine if BMI influences cardiovascular event risk following PCI.

Main Methods:

  • Secondary analysis of a retrospective cohort study involving 204 patients with stable CAD.
  • Patients were categorized into underweight (BMI <18.5 kg/m²), normal BMI (18.5–24.9 kg/m²), and overweight (BMI ≥25 kg/m²).
  • Primary endpoint was MACE, with follow-up for a median of 783 days.

Main Results:

  • Overweight patients (BMI ≥25 kg/m²) exhibited significantly fewer MACE compared to normal BMI individuals (OR=0.17; 95% CI: 0.03–0.84).
  • No significant difference in MACE was observed between underweight and normal BMI groups (OR=1.73; 95% CI: 0.42–7.17).
  • BMI positively correlated with hemoglobin and albumin, and negatively with HDL cholesterol. The optimal BMI threshold for MACE prediction was 24.23 kg/m² (AUC=0.729).

Conclusions:

  • Overweight status in stable CAD patients is associated with a reduced risk of MACE after PCI.
  • An optimal BMI threshold of 24.23 kg/m² can aid in predicting MACE in this patient population.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
813
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
720
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
713
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
281
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
348